Expert Interview
A second look at the FDA decision to lift the hold on Bluebird Bio's lovotibeglogene autotemcel (lovo-cel) sickle cell disease therapy
Ticker(s): BLUEInstitution: Rutgers Medical School
- Interim Chief, Pediatric Hematology/Oncology and Director, Comprehensive Sickle Cell Center at Rutgers Cancer Institute of New Jersey; Vice Chair, IRB at Rutgers Biomedical and Health Sciences; and Vice Chair, NCI Pediatric Central IRB.
- Currently manages 450 patients with sickle cell disease.
- Research focuses on Hodgkin Disease, Pediatric oncology/ hematology, and Sickle cell disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
